Evidence map›Paper›PMID 28624994›Full record

ArticleClinical & experimental metastasis2017

Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.

M Bartova, J Hlavaty, Y Tan, C Singer, K Pohlodek, J Luha, I Walter

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

M Bartova2nd Department of Obstetrics and Gynecology, University Hospital Bratislava, Ružinovská 6, Bratislava, 826 06, Slovakia. michaelabart@gmail.com.ORCID 0000-0003-0984-8430
J HlavatyDepartment of Pathobiology, Institute of Anatomy, Histology and Embryology, University of Veterinary Medicine, Veterinärplatz 1, 1210, Vienna, Austria.
Y TanDepartment of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
C SingerDivision of General Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
K Pohlodek2nd Department of Obstetrics and Gynecology, University Hospital Bratislava, Ružinovská 6, Bratislava, 826 06, Slovakia.
J LuhaFaculty of Medicine, Institute of Medical Biology, Genetics and Clinical Genetics, Comenius University Bratislava, Sasinkova 4, Bratislava, 811 08, Slovakia.
I WalterDepartment of Pathobiology, Institute of Anatomy, Histology and Embryology, University of Veterinary Medicine, Veterinärplatz 1, 1210, Vienna, Austria.
University Hospital Bratislava · SKUniversity of Veterinary Medicine Vienna · ATComenius University Bratislava · SKMedical University of Vienna · ATQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ezrin, radixin, moesin (ERM) are important membrane-cytoskeletal crosslinkers and are suggested to play important role in cancer progression and metastasis. Even though ERM proteins were generally considered to be functionally redundant and the most studied was ezrin, recent studies highlight their distinct roles in metastatic process. Little information is available regarding the role of individual ERM proteins and their phosphorylated forms in human breast cancer. Our study is the first to examine expression of ezrin, moesin and their phosphorylated forms in primary breast tumors and matched lymph node metastases (LNMs) and their correlation with clinicopathological variables. A total of 88 primary breast cancer, 91 LNMs, 54 intraductal carcinoma and 26 normal adjacent breast tissue samples from tissue microarrays were studied. Expression was determined by immunohistochemistry, the intensity and number of positive cells was scored. Statistical analysis of protein expression and patients' age, tumor grade and hormonal status was performed. No statistical significant difference was found in ezrin, moesin, p-ezrinTyr353 and pan-p-ezrinThr567/radixinThr564/moesinThr558 expression between primary tumors and LNMs. Even though it was not significant, moesin expression varied between primary tumors, intraductal carcinoma, normal breast adjacent tissue and LNMs. A significant positive correlation between moesin and tumor grade has been proven. Even though primary tumors and matched LNMs did not show different expression patterns, moesin correlated significantly with higher tumor grade. Its positivity in intraductal carcinoma and normal breast tissue adjacent to cancer might indicate its role in tumor intiation/progression.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCytoskeletal ProteinsEzrinFemaleHumansLymphatic MetastasisMCF-7 CellsMicrofilament ProteinsMiddle AgedPhosphoproteinsCytoskeletal ProteinsEzrinMicrofilament ProteinsmoesinPhosphoproteinsBreast cancer metastasisEzrinMoesinPhosphorylation

Identifiers

PMID28624994
OpenAlexW2624803069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.